Irbesartan/Trichlormethiazide

厄贝沙坦/三氯噻嗪

Report date: 2022/01/14 13:23:58

Base Information

Drug NameIrbesartan/Trichlormethiazide
Drug Alias Nameイルベサルタン・トリクロルメチアジド配合剤三氯噻嗪/厄贝沙坦Trichlormethiazide/IrbesartanIrbesartan - trichlormethiazideirbesartan and trichlormethiazide +[8] 
ClassificationSmall molecules
Mechanisms of ActionThiazide-sensitive sodium-chloride cotransporter inhibitorsAngiotensin II Receptor Type 1 antagonists
TargetsThiazide-sensitive sodium-chloride cotransporterAngiotensin II Receptor Type 1
Therapy Area/IndicationsHypertension
Global Approved IndicationsHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2013/06/28
Country/TerritoryJapan
CombinationsYes IrbesartanTrichlormethiazide
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesShionogi & Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShionogi & Co Ltd
Inactive CompaniesN/A
Active IndicationsHypertension
Inactive IndicationsN/A

Other Information

ATC CodeC09DA04
Related LinksKEGG